---
document_datetime: 2023-09-21 18:26:12
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ablavar-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: ablavar-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6701463
conversion_datetime: 2025-12-24 09:30:18.073766
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Ablavar

Procedural steps taken and scientific information after the authorisation

| No       | Scope                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3 longer   | Summary                                                                                                                                                                                                                       |
|----------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0020  | C.I.z - Changes (Safety/Efficacy) to Human and Veterinary Medicinal Products - Other variation                           | 15/05/2011                          | n/a                                         | SPC, Labelling, PL                      | To update the Summary of Product Information, Labelling and Package Leaflet in order to express the quantitative composition in term of the mass of the active moiety (i.e. 'gadofosveset' and not 'gadofosveset trisodium'). |
| IA/0019  | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for Centrally Authorised products | 10/01/2011                          | n/a no                                      | SPC, Labelling, PL                      |                                                                                                                                                                                                                               |
| R/0018   | Renewal of the marketing authorisation                                                                                   | 19/08/2010 product                  | 25/10/2010                                  | SPC, Annex II, Labelling, PL            |                                                                                                                                                                                                                               |
| A20/0015 | Article 20 Review                                                                                                        | 19/11/2009                          | 10/06/2010                                  |                                         | Please refer to the assessment report published after deletion of commercially confidential information: EMEA/H/0601/A-20/0015.                                                                                               |
| IA/0017  | A.1 - Administrative change - Change in the name and/or address of the MAH                                               | 09/03/2010                          | n/a                                         | SPC, Labelling, PL                      |                                                                                                                                                                                                                               |
| T/0016   | Transfer of Marketing Authorisation Holder                                                                               | 04/06/2009                          | 18/06/2009                                  | SPC, Labelling, PL                      |                                                                                                                                                                                                                               |
| II/0014  | Change to SPC section 4.8 and compliance                                                                                 | 30/05/2008                          | 07/07/2008                                  | SPC, Annex II,                          | The product information for Vasovist has been amended to                                                                                                                                                                      |

<!-- image -->

7 Westferry Circus

●

Canary Wharf

●

London E14 4HB

●

United Kingdom

Telephone

+44 (0)20 7418 8400 Facsimile +44 (0) 20 7523 7455

E-mail

info@ema.europa.eu Website www.ema.europa.eu

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         | with QRD template Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                                                                                                                                                                                                                                                                                                           |                                     | no                                          | Labelling, PL                    | update section 4.8 Undesirable effects of the SPC following the results of four additional clinical studies. Clinical trial experience is now based on more than 1,800 patients and the undesirable effects observed have been updated. Consequently, the following adverse reactions with the frequency 'uncommon' were added: \"confusion\", \"peripheral coldness\", \"pruritus ani\", \"vision abnormal\", \"genital pruritus\" and \"genital burning sensation\".The adverse reaction \"swelling face\" was added with a frequency rare. The frequency of the following adverse events has been increased from rare to uncommon: \"electrolyte imbalance\", \"feeling hot\", \"cough\", \"muscle contractions involuntary\", \"dyspepsia\", \"pharyngolaryncheal pain\" and \"electrocardiogram abnormal\". The Package leaflet has been amended accordingly. The product information (SPC, Annex II, labelling and Package Leaflet) were also reformatted to the latest QRD template version 7.2. longer authorised |
| II/0012 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                         | 21/02/2008                          | 28/02/2008                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0013 | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                                                                                                                                                                                          | 21/02/2008                          | 28/02/2008                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0011 | Update of section 4.4 of the SPC with a warning on nephrogenic systemic fibrosis (NSF) associated with gadolinium-containing contrast agents in patients with severe renal impairment, further to a request from the CHMP. The Package Leaflet has been updated accordingly. The list of local representatives has also been updated in the Package Leaflet. Update of Summary of Product Characteristics and Package Leaflet Medicinal | 20/09/2007 product                  | 23/10/2007                                  | SPC, PL                          | The MAH applied to update section 4.4 of the SPC with a warning on nephrogenic systemic fibrosis (NSF) associated with gadolinium-containing contrast agents in patients with severe renal impairment, further to a request from the CHMP. The Summary of Product Characteristics was amended as follows: 4.4 Special Warnings and Precautions for use […] Renal impairment Impaired renal function Since gadofosveset is cleared from the body primarily by urinary excretion, caution should be exercised in patients with impaired renal function (See Section 5.2). Dose adjustment in renal impairment is not necessary. In patients with more severely impaired renal function (clearance < 20 ml/min) who are not supported by routine dialysis, the benefits must be weighed very carefully against the risks. In a clinical trial it was shown that gadofosveset can effectively be                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         | Medicinal                               | product                             | no                                          | longer                           | removed from the body by dialysis using high flux filters. There have been reports of Nephrogenic Systemic Fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR< 30ml/min /1.73 m2). - acute or chronic severe renal impairment (GFR< 30ml/min /1.73 m2) or - acute renal insufficiency of any severity due to the hepato- renal syndrome or in the perioperative liver transplantation period. As there is a possibility that NSF may occur with Vasovist, it should therefore only be used in these patients after careful risk/benefit assessment consideration and if the diagnostic information cannot be obtained by other means. . Haemodialysis has not been established as an effective treatment option for patients with NSF. All patients should be screened, in particular patients over the age of 65, for renal dysfunction by obtaining a history and/or laboratory tests. Haemodialysis shortly after Vasovist administration in patients currently receiving haemodialysis may be useful at removing Vasovist from the body. In a clinical trial it was shown that gadofosveset can effectively be removed from the body by dialysis using high flux filters. There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis. The Package Leaflet has been updated accordingly. authorised |
| II/0008 | Quality changes                         | 26/04/2007                          | 04/06/2007                                  | SPC                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0007 | Quality changes                         | 26/04/2007                          | 03/05/2007                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0009 | Quality changes                         | 26/04/2007                          | 03/05/2007                                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0010 | 01_Change in the name and/or address of | 30/03/2007                          | n/a                                         | SPC, Annex II,                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006 | the marketing authorisation holder Update of Summary of Product Characteristics section 4.4 and Package Leaflet Update of Summary of Product Characteristics and Package Leaflet | 22/02/2007                          | 14/03/2007                                  | Labelling, SPC, PL               | PL Upon request of the PhVWP and CHMP the MAH updated section 4.4 of the SPC regarding the risk of nephrogenic systemic fibrosis (NSF) in patients with severe renal failure. The PIL is amended accordingly. authorised |
| II/0005 | Update of or change(s) to the pharmaceutical documentation                                                                                                                       | 18/10/2006                          | 24/10/2006                                  | longer                           |                                                                                                                                                                                                                          |
| II/0004 | Update of or change(s) to the pharmaceutical documentation                                                                                                                       | 18/10/2006                          | 24/10/2006                                  |                                  |                                                                                                                                                                                                                          |
| IA/0003 | 11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                    | 10/03/2006                          | n/a                                         |                                  |                                                                                                                                                                                                                          |
| II/0002 | Change(s) to the manufacturing process for the active substance                                                                                                                  | 23/02/2006                          | 27/02/2006                                  |                                  |                                                                                                                                                                                                                          |

Medicinal product no longer authorised